



विशाल चौहान, भा.प्र.से.
संयुक्त सचिव

VISHAL CHAUHAN, IAS

Joint Secretary



भारत सरकार
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
निर्माण भवन, नई दिल्ली - 110011

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
NIRMAN BHAVAN, NEW DELHI - 110011

Tele: 011-23063585 / 23061740

e-mail: js.policy-mohfw@gov.in

D.O. No. NHSRC/13-14/QI/01/DPSEPF-2

Dated: 20th February 2023

Dear Colleagues

As you are aware, Thalassemia is one of the inherited disorders of red blood cells and imposes a heavy financial and emotional burden on families. The two forms of Thalassemia i.e. Thalassemia Major and the severe form of Thalassemia Intermedia constitutes a major burden of disease, as management of both forms require lifelong regular blood transfusion and iron chelation to remove the excessive iron overload, consequent to the multiple blood transfusion.

2. In order to ensure the availability of iron chelation drugs at health facilities, it is decided to add oral iron chelating agents in Essential Medicine Lists (EDLs) under Free Drug Service Initiative, NHM. The oral iron chelating agents Deferiprone and Deferasirox is to be added at District Hospital (DH) and Sub District Hospital (SDH) level facilities (Revised EDL at SDH and DH is enclosed herewith).

3. The revised EDL includes 377 medicines at DH and 313 medicines at SDH level. Hence, all the States/UTs are requested to strive for making these essential medicines available in sufficient quantities at DH and SDH level health facilities to reduce the out-of-pocket expenditure bear by Thalassemia patients on iron chelation medicines.

With regards

Encl: as above

Yours Sincerely,


(Vishal Chauhan)

ACS/PS/Secretary (H&FW) - All states/UTs

Copy

- MDs (NHM)- All states/UTs
- PSO to Secretary (H&FW), MoHFW
- Sr.PPS to AS& MD (NHM), MoHFW
- PS to ED(NHSRC)